Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

Income Statement

Follow revenue through to earnings.

Revenue

$1.36M

FY 2025 · Annual

Operating Income

-$13.04M

FY 2025 · Annual

Net Income

-$11.92M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

COEP Earnings Waterfall · TTM

NASDAQ:COEP · Revenue to Net Income

Key Ratios

EPS$-2.47
Gross Margin78.4%
Net Margin-1658.1%
P/E Ratio-5.8
P/S Ratio289.5

Analysis

$1.4M of revenue converted into -$11.9M of net income for the selected period. Gross margin is 78.4% and net margin is -1658.1%, showing how much revenue survives after costs and taxes. EPS is $-2.47, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
424B3424B3 filingJun 18, 2026
EFFECTEFFECT filingJun 16, 2026
POS AMPOS AM filingJun 16, 2026
S-1S-1 filingJun 9, 2026
4Statement of changes in beneficial ownershipJun 8, 2026

How much revenue does COEP generate?

Coeptis Therapeutics, Inc. (COEP) reported $1.36M of revenue in fiscal 2025.

Is COEP profitable?

Coeptis Therapeutics, Inc. (COEP) reported -$11.92M of net income, with a net margin of -874.3%.